The Effects of Fermented Brown Seaweed Intake on Glucose Metabolism and Gut Health - Trial NCT06418763
Access comprehensive clinical trial information for NCT06418763 through Pure Global AI's free database. This phase not specified trial is sponsored by Aventure AB and is currently Recruiting. The study focuses on Healthy Subjects. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Aventure AB
Timeline & Enrollment
N/A
Apr 22, 2024
Jun 30, 2025
Primary Outcome
Postprandial blood glucose
Summary
The aim of this randomised, controlled, cross-over study is to investigate whether the intake
 of fermented brown seaweed can lower postprandial blood glucose levels and influence the
 composition of the gut microbiota in 25 healthy volunteers. Well-being and gastrointestinal
 symptoms as well as sensory properties of the products will also be evaluated using
 questionnaires.
 
 At the screening visit, the subjects will be informed about the study procedures and
 inclusion/exclusion criteria will be checked. Informed consent will be signed by each subject
 before participating in the study. The participants will consume the active and control
 product, respectively, for 5 days with a 14-day wash-out period in between. Capillary blood
 samples will be drawn for glucose measurement at the first day of each 5-day intervention
 period. Faecal samples will be collected before and after each 5-day intervention period to
 analyse changes in gut microbial composition.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06418763
Non-Device Trial